StreetInsider.com News Articles

Better 2.0 Publishes Weekly Report Card, Week 2: Sales Efficiency and Cost Cutting

Tue, 20 Oct 2026 17:22:00 -0400

Actions to date expected to deliver $22.56 million in annualized savings toward the approximately $64.2 million target

NEW YORK--(BUSINESS WIRE)-- Better Home & Finance Holding Company (NASDAQ: BETR) today released Week 2 of its Better 2.0 Weekly Report Card, a public record of the company’s turnaround published every Tuesday.

Since October 13, Better has taken additional actions expected to generate $9.36 million in annualized savings. Combined with the ~$13.2 million in annualized reductions initiated in the first week, Better expects these actions to deliver $22.56 million in annualized savings as it works toward a target of approximately $64.2

Better 2.0 Publishes Weekly Report Card, Week 2: Sales Efficiency and Cost Cutting

Tue, 20 Oct 2026 17:22:00 -0400

Actions to date expected to deliver $22.56 million in annualized savings toward the approximately $64.2 million target

Form 4 Better Home & Finance For: Sep 01 Filed by: Garg Vishal

Tue, 20 Oct 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20261020/27211106.html

Form 3 Better Home & Finance For: Oct 05 Filed by: Nicholas J. Calamari

Tue, 20 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261020/27211081.html

Form 4 Better Home & Finance For: Oct 01 Filed by: Tuffin Paula

Tue, 20 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261020/27211054.html

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Better Home & Finance Holding Company to Contact Law Firm

Mon, 19 Oct 2026 19:28:00 -0400

Better Home & Finance Holding Company (NASDAQ: BETR) shareholders should email fletcher@fmoorelaw.com

NEW YORK, Oct. 19, 2026 /PRNewswire/ --

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Better Home & Finance Holding Company to Contact Law Firm

Mon, 19 Oct 2026 19:28:00 -0400

Better Home & Finance Holding Company (NASDAQ: BETR) shareholders should email fletcher@fmoorelaw.com

NEW YORK, Oct. 19, 2026 /PRNewswire/ --

Form 144 Better Home & Finance Filed by: Tuffin Paula

Mon, 19 Oct 2026 14:54:00 -0400

si-local-file:///var/storage/secattach/20261019/27203420.html

Form 144 Better Home & Finance Filed by: Nicholas J. Calamari

Mon, 19 Oct 2026 14:43:00 -0400

si-local-file:///var/storage/secattach/20261019/27203378.html

BetterLife Pharma names Richard Lipton as SAB co-chair

Mon, 19 Oct 2026 08:01:20 -0400

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF, FSE: NPAU) has appointed Professor Richard B. Lipton, MD, as co-chair of its Scientific Advisory Board, the company announced in a press release dated October 19, 2026.

Dr. Lipton holds the Edwin S. Lowe Chair in Neurology and serves as vice chair of the Saul R. Korey Department of Neurology at Albert Einstein College of Medicine. He is also director of the Montefiore Headache Center in New York and a past president of the American Headache Society. He has authored more than 1,200 peer-reviewed publications.

Dr. Lipton joins Professor Peter Goadsby, MD, PhD, FRS, whose

BetterLife Pharma names Richard Lipton as SAB co-chair

Mon, 19 Oct 2026 08:01:20 -0400

Dr. Lipton joins Professor Peter Goadsby, MD, PhD, FRS, whose

BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board

Mon, 19 Oct 2026 08:00:00 -0400

Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001

Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the appointment of Professor Richard B. Lipton, MD, as Co-Chair of its Scientific Advisory Board ("SAB"). Professor Lipton joins Professor Peter Goadsby, MD, PhD, FRS, whose appointment as Co-Chair was announced on October 14, 2026.

Dr. Lipton is the Edwin S.

BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board

Mon, 19 Oct 2026 08:00:00 -0400

Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001

Dr. Lipton is the Edwin S.

BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board

Mon, 19 Oct 2026 08:00:00 -0400

Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001

Dr. Lipton is the Edwin S.

BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board

Mon, 19 Oct 2026 08:00:00 -0400

Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001

Dr. Lipton is the Edwin S.

Form SCHEDULE 13G/A Better Home & Finance Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Fri, 16 Oct 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20261016/27198895.html

Form 3 Better Home & Finance For: Oct 05 Filed by: GORDON WILLIAM B

Fri, 16 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261016/27198312.html

Form 3 Better Home & Finance For: Oct 05 Filed by: Sarracino Steven

Thu, 15 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261015/27193271.html

Former X CEO Linda Yaccarino joins Better's board of directors

Thu, 15 Oct 2026 10:33:16 -0400

Better Home & Finance Holding Company (NASDAQ: BETR) announced that Linda Yaccarino, former chief executive officer of X, has joined its board as an independent director, effective October 15, 2026.

Yaccarino is described as the first director appointed under the company's Better 2.0 initiative. According to a press release, her stated priorities will include expanding use of Better's Tinman AI platform, cost discipline, and shareholder value.

"Better is making life's largest financial decision for an American family more affordable, more accessible, and more transparent with AI. I am excited to be a part of something so important," Yaccarino said.

Before joining X, Yaccarino

Former X CEO Linda Yaccarino Joins Better’s Board as Independent Director to Scale AI-Native Homeownership

Thu, 15 Oct 2026 10:33:00 -0400

One of the best-known executives in media, enterprise partnerships and technology joins as Better launches Better 2.0

NEW YORK--(BUSINESS WIRE)-- Better Home & Finance Holding Company (NASDAQ: BETR) (“Better” or the “Company”), the leading AI-native home finance company, today announced that Linda Yaccarino, former Chief Executive Officer of X, has joined the Board as Independent Director effective October 15, 2026.

“Better is making life’s largest financial decision for an American family more affordable, more accessible, and more transparent with AI. I am excited to be a part of something so important,” said Yaccarino. “When we were building X

Former X CEO Linda Yaccarino Joins Better’s Board as Independent Director to Scale AI-Native Homeownership

Thu, 15 Oct 2026 10:33:00 -0400

One of the best-known executives in media, enterprise partnerships and technology joins as Better launches Better 2.0

BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations

Thu, 15 Oct 2026 08:00:00 -0400

Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations.

In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead candidate, before the program advances into chronic cluster headache and chronic migraine.

Ms. Leitzinger brings nearly

BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations

Thu, 15 Oct 2026 08:00:00 -0400

Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine

Ms. Leitzinger brings nearly

BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations

Thu, 15 Oct 2026 08:00:00 -0400

Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine

Ms. Leitzinger brings nearly

BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations

Thu, 15 Oct 2026 08:00:00 -0400

Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine

Ms. Leitzinger brings nearly